Clinical Trials
1123
194 active
Approvals
0
Total approvals
Agencies
0
Regulatory bodies
Founded
1710
Active, not recruiting
153
13.6%
Completed
516
46.0%
Enrolling By Invitation
2
0.2%
Not yet recruiting
39
3.5%
Recruiting
188
16.7%
Suspended
6
0.5%
Terminated
46
4.1%
Unknown
154
13.7%
Withdrawn
19
1.7%
No approval data available
- A ten-week randomized trial found dronabinol, a cannabis-derived THC medication, reduced PTSD nightmare scores by 3.66 points versus 2.17 for placebo, a statistically significant difference. - Complete nightmare remission was achieved in 36.8% of patients on dronabinol compared to 14.5% on placebo, with 57.9% seeing scores at least halved. - Sleep quality improved significantly, though clinician-rated overall PTSD severity and depression scores did not shift, suggesting a nightmare-specific benefit. - Side effects were mostly mild to moderate, with dizziness, increased appetite, and dry mouth most common; no severe adverse events were attributed to the drug.
- Researchers from Berlin and Würzburg identified oxalate as a driver of systemic inflammation and heart damage through IL-17A-mediated immune activation in mice. - Blocking IL-17A in animal models simultaneously improved kidney function, reduced inflammation and fibrosis, and decreased cardiac damage. - Elevated IL-17A levels were also confirmed in patients with primary hyperoxaluria, strengthening the translational relevance of the oxalate–IL-17A–cardiorenal injury axis. - The findings suggest oxalate should no longer be viewed solely as a kidney stone-forming substance but as a systemic burden on the immune system and metabolism.
- Europe's largest privately funded ME/CFS research programme is investing €2.4 million across seven new projects at eight German research institutions, including Charité Berlin and Heidelberg University Hospital. - Funded projects will investigate B-cell depletion therapy, genetic causes, biomarkers for diagnosis, autoimmunity, immunological mechanisms in children, and machine learning-assisted biomarker development. - ME/CFS affects over 657,000 people in Germany and more than 40 million worldwide, with 60–75% unable to work and no curative treatments currently available. - The DISCOVER-ME international project led by MedUni Vienna will analyze over 700 patient samples using multi-omics methods and screen 9,000 existing drugs for potential repurposing.
- A prospective single-center study of 194 patients found genicular artery embolization (GAE) using rapidly resorbable gelatin-based microspheres provided significant and sustained knee osteoarthritis pain relief for at least 12 months. - Median pain scores on the Numeric Rating Scale dropped from 7 before treatment to 3 at both 6- and 12-month follow-ups, with 80% of participants achieving clinically meaningful improvement at one year. - Every procedure was technically successful with no moderate or severe adverse events; only 6.7% of participants experienced mild, self-resolving reactions. - GAE represents a minimally invasive, nonsurgical option filling the treatment gap between conservative measures and total knee replacement for patients with osteoarthritis-related knee pain.
- Researchers at EMBL Hamburg and FMP Berlin mapped direct virus-host protein contacts inside intact influenza A-infected cells for the first time using a specialized cross-linking mass spectrometry workflow. - The study revealed that influenza A dissolves paraspeckles in the nucleus, releasing RNA-binding proteins that the virus exploits for replication, a strategy conserved across multiple flu strains. - Combining XL-MS data with a modified AlphaFold algorithm enabled structural modeling of how viral and host proteins physically fit together, identifying potential actionable drug targets. - The approach lays groundwork for studying pandemic-relevant viruses like H5N1 and provides a broadly applicable method for mapping native virus-host interactions across infection cycles.
- A randomized trial of the SUPPORT+ app showed patients with advanced cancer in palliative care maintained superior quality of life over 18 weeks compared with usual care (P < .001). - The PRO B digital care concept, tested across 52 German breast cancer centers and 909 patients, significantly reduced fatigue and improved physical functioning in metastatic breast cancer. - Both interventions reduced unplanned hospitalizations, with the SUPPORT+ group showing a significantly lower rate of worsening hospitalization episodes (17.2% vs. 28.5%; OR = 0.52). - Germany's Federal Joint Committee (G-BA) recommended incorporating the PRO B concept into standard care, with rollout under the name "ida" expected this autumn.
- SCIRENT announced the appointment of Prof. Dr. Wilhelm Haverkamp as Chief Medical Officer, bringing over three decades of expertise in cardiac electrophysiology and drug safety to strengthen the company's clinical oversight capabilities. - Prof. Haverkamp will focus on expanding structured safety services, including establishing Data Safety Monitoring Committees and Clinical Event Committees for enhanced patient safety in clinical research. - The appointment reinforces SCIRENT's strategic commitment to advancing clinical research quality through strong medical leadership, with Prof. Haverkamp's extensive experience in cardiovascular medicine and artificial intelligence-enhanced cardiac diagnostics. - With more than 420 peer-reviewed publications and extensive experience as principal investigator in clinical trials, Prof. Haverkamp brings internationally recognized expertise in arrhythmias, heart failure, and cardiogenetics to the cardiovascular research organization.
- German regulatory authority BfArM has approved an optimized design for Isofol Medical's ongoing phase Ib/II study of arfolitixorin, expanding inclusion criteria from 45% to 90% of colorectal cancer patients. - The phase II portion will now include a control arm for direct comparison with leucovorin, the current leading folate-based medicine, strengthening the trial's robustness. - Study expansion includes additional chemotherapy regimens and will increase from one to 10-15 study centers across multiple European countries to accelerate patient recruitment. - Arfolitixorin is being developed to enhance the efficacy of established cancer treatments for colorectal cancer, the world's third most common cancer with significant unmet medical need.
- Sildenafil, the active ingredient in Viagra, demonstrated significant improvements in muscle strength and neurological symptoms in six Leigh syndrome patients aged 9 months to 38 years. - One child's walking distance increased tenfold from 500 to 5,000 meters, while another patient stopped experiencing seizures and two others showed cognitive improvements. - The European Medicines Agency has granted sildenafil orphan drug designation for Leigh syndrome, paving the way for a larger placebo-controlled trial across Europe. - This represents the first promising treatment candidate for Leigh syndrome, a rare genetic disorder affecting one in 40,000 births with no currently approved therapies.
- DiNAQOR and academic partners published a landmark study in JACC: Basic to Translational Science demonstrating a first-in-class percutaneous catheter-based closed-loop perfusion platform for organ-isolated delivery of advanced therapies. - The platform achieved up to 69,000-fold higher local payload concentration and 75-fold increase in target-organ transduction efficiency compared to conventional intravenous administration in large-animal models. - Mayo Clinic experts endorsed the technology as a "game-changer" that closes the gap between promise and precision in gene delivery by enabling scalable, outpatient-compatible precision delivery across multiple organs. - DiNAQOR spun out the technology into DiNATEQ AG to focus initially on kidney-targeted gene therapy while preserving broader platform potential for future indications and partnerships.
